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Radiotherapy applies ionizing irradiation to selected areas of the body with the scope of destroying cancer cells, either as
part of curative therapies to remove a primary malignant tumor and to prevent tumor recurrence after surgery, or as part
of palliative measures to avoid local advancement of bone and brain metastases. Intriguingly, radiotherapy does not only
have local effects but may lead to the delayed regression of distant non-irradiated lesions. Most likely, these “abscopal”
effects are mediated by the immune system.
Radiation oncologists have been reporting
for a long time the so-called “abscopal”
effect, denoting the impact that irradiation
of a tissue has on remote non-irradiated
tissues.
1 Beyond unwarranted side effects
of radiotherapy, this “abscopal” effect may
also be therapeutic, at least in some
peculiar cases. Thus, occasionally, distant
metastases, which have not been irra-
diated, exhibit a delayed therapeutic
response, as this has been documented
for example for melanoma,
2 lymphoma,
3
adenocarcinoma,
4 hepatocellular carcin-
oma
5 or Merkel cell carcinoma.
6
Clinicians initially attempted to explain
the abscopal effect by a radiation-induced
increase in the circulating levels of cyto-
kines such as tumor necrosis factor
5 or
interleukin-18.
7 However, recent evidence
suggests that local radiotherapy can elicit
an immune response whose effectors, most
likely T lymphocytes, then migrate to
distant lesions provoking their regression.
Indeed, there is convincing evidence
that the therapeutic abscopal effect is
mediated by an anticancer immune
response, at least in mice. First, the
abscopal effect can be increased by inject-
ing bone marrow-derived dendritic cells
into the irradiated lesion, after radio-
therapy,
8 or by administering immunosti-
mulatory factors such as MIP-1a,
9 toll-like
receptor-9 agonists
10 or anti-CTLA anti-
body.
11 The abscopal effect correlated with
the induction of IFNc-producing T cells
11
and was abolished by depletion of CD4
+
or CD8
+ T lymphocytes.
9 Moreover,
irradiation can induce immunogenic cell
death, thus converting dying cancer cells
into a therapeutic vaccine,
12 and that
radiotherapy is more efficient in immuno-
competent mice than in mice lacking
TLR4 that are unable to mount an
immune response against dying tumor
cells.
13 Hence, the abscopal effect may be
mediated by an anticancer immune
response that is triggered by radiation-
induced immunogenic cell death.
Accordingly, both external-beam radio-
therapy and brachytherapy can induce
anticancer immune responses in patients
with prostate canceror colorectalcancer.
14,15
In the March 8 issue of the New
England Journal of Medicine,
16 a team of
researchers at Memorial Sloan Kettering
Cancer Center report the case of a patient
with NY-ESO-1+ melanoma treated by
local radiotherapy and systemic injections
of the anti-CTLA antibody, ipilimumab,
both before and after radiation. In this
patient, palliative irradiation of a para-
spinal thoracic mass led to the regression
of distant lesions, in particular a hilar
lymphadenopathy and splenic lesion. This
response temporarily correlated with signs
of anti-melanoma immune response,
namely an increase in NY-ESO-1-specific
antibodies, as well as a raise in the frequency
of circulating CD4
+ T cells expressing the
activation marker ICOS, NY-ESO-1-
specific interferon-c–producing CD4
+ cells,
and HLA-DR-expressing CD14
+ mono-
cytes.
16 These data plead in favor of the
interpretation that abscopal effects of radio-
therapy are indeed mediated by specific
anticancer immune responses.
The aforementioned results may have
far-reaching implications for the future
amelioration of radiotherapies. How can
this new knowledge be rendered useful?
First, it remains to be determined which
dose and which fractionation schedule
11
can induce an optimal combination of
immunogenic cancer cell death and deple-
tion of local immunosuppressive cells
without destroying essential positive
immune effectors at the irradiation site.
Second, it will be important to determine
which regimen of (local or systemic?)
immunostimulation would facilitate post-
radiation anticancer immune responses.
We anticipate that an optimal combina-
tion of radiotherapy and immunotherapy
will elevate abscopal effects to a systema-
tically achievable rather than anecdotic
therapeutic goal.
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